Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023
November 01, 2023 16:01 ET
|
Immunocore Holdings Limited
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 01 November 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a...
Immunocore to present at upcoming investor conferences
October 30, 2023 16:30 ET
|
Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 30 October 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a...
Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial
October 21, 2023 08:45 ET
|
Immunocore Holdings Limited
Data published in New England Journal of Medicine and presented as a late breaking abstract in mini oral session at ESMO Congress 2023 KIMMTRAK demonstrated long-term survival benefit in HLA-A*02:01...
Immunocore announces upcoming presentation and posters at ESMO 2023
October 06, 2023 07:01 ET
|
Immunocore Holdings Limited
Immunocore announces upcoming presentation and posters at ESMO 2023 Long-term survival data for KIMMTRAK in previously untreated patients with metastatic uveal melanoma to be presented as a...
Immunocore to present at upcoming investor conferences
September 11, 2023 17:00 ET
|
Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 September 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a...
Immunocore to present at upcoming investor conferences
September 01, 2023 16:00 ET
|
Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 01 September 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a...
Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 07:00 ET
|
Immunocore Holdings Limited
Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £45.5 million ($57.8 million) in 2Q 2023; new launches in Italy, Austria,...
Immunocore to report second quarter 2023 financial results and host call on August 10, 2023
August 03, 2023 08:00 ET
|
Immunocore Holdings Limited
Immunocore to report second quarter 2023 financial results and host call on August 10, 2023 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 03 August 2023) Immunocore...
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
June 03, 2023 07:00 ET
|
Immunocore Holdings Limited
Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 3...
Immunocore to present at upcoming investor conferences
June 01, 2023 16:30 ET
|
Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 01 June 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a...